25dimethoxy4bromophenethylamine

25-dimethoxy-4-bromophenethylamine is a substituted phenethylamine in the NBOMe class of synthetic hallucinogens. The name references a benzene ring with two methoxy groups at the 2- and 5-positions, a bromine at the 4-position, and an N-(2-methoxybenzyl) group attached to the amine. Compounds in this family are typically encountered as research chemicals and lack established medical uses.

Chemistry and structure: The compound features a 1-phenethylamine core with a 2,5-dimethoxy substitution pattern on the aromatic ring and a 4-bromo substituent, plus the NBOMe N-aryl substituent. This structural arrangement is characteristic of NBOMe derivatives, which are known for high potency at serotonergic targets and for being studied primarily in non-clinical contexts.

Pharmacology: NBOMe derivatives act as potent agonists at the serotonin 5-HT2A receptor and are associated with psychedelic effects at relatively small exposures. Their high potency increases the risk of adverse reactions and overdose, including cardiovascular and neurologic symptoms. They are not approved for medical use and safety data are limited outside controlled research settings.

Legal status: In many jurisdictions NBOMe derivatives are controlled substances or illegal analogs, with specific classifications varying by country. Many regions regulate these compounds due to their potential for abuse and safety concerns. They are not approved for clinical use and are typically encountered only in illicit markets or specialized research contexts.

Safety: Use can cause agitation, tachycardia, hypertension, hyperthermia, seizures, and other serious outcomes. There is no accepted therapeutic application, and products may be mislabeled or adulterated. If exposure is suspected, seek immediate medical attention.